4-6 Collaboration Agreements
Encompass, the home health segment of HealthSouth, plans to become a collaborator in Medicare’s Comprehensive Care for Joint Replacement (CJR) bundled payment initiative. Encompass will risk losing a percentage of reimbursement if they and fellow collaborators fail to improve quality and efficiency based on the CJR’s measures. Few, if any, home care companies have put skin in the game like this, and Encompass is starting small, with 4-6 agreements, but to roll out the lessons learned into many more of their markets.
Wyatt Matas estimates that the private duty home care industry is growing at 6-8% per year, with revenues approaching $30 billion annually. Investors have taken notice of the growth and opportunity to fill a need in the healthcare continuum and are looking to invest in home care. More than $200 million has been invested in the past 30 months.
2.4 Billion Hours
The New York Times estimates that American spend 2.4 billion hours annually on doctor visits, only 17% of which is spent with the doctor. That equates to $52 billion, or the total working time and income of 1.2 million people. Employers are offering telehealth options, with 90% of large employers planning to offer an option next year. Now to just get payers, HIPAA, providers and patients fully on board.
TytoCare, an Israeli-based telehealth startup, has raised over $19M to fund their user-friendly exam tools. Patients gather exam information on ears, throat, skin, heart, lungs and temperature in their homes for telehealth appointments. The CEO, Dedi Gilad, hopes that the addition of exam data and images will boost the effectiveness and therefore utilization of telehealth appointments.
Adrenaclick, the little-known competitor of the EpiPen, has managed to secure only 7% of the market, despite the lower cost (around $400 out-of-pocket, compared with more than $600). Missteps abound in the 13 years since it was released, including undercapitalization, frequent changes of name and ownership, an inability to keep up with demand, a year off the market, a version that was difficult to use, and a lack of marketing and brand awareness. Comparing the trajectories of EpiPen with the Adrenaclick is a lesson in do’s and don’t’s.